Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Has this study been replicated?
The atlas records 2 replications of this study. Recorded outcomes: 2 failed. The earliest on record is from 2016.
Replications
- Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs, Mantis et al. (2017). eLife. Outcome recorded: failed.
we found that coadministration with iRGD peptide did not have an impact on permeability of the chemotherapeutic agent doxorubicin (DOX)
Outcome read from the abstract. View paper - Study 15: Replication of Sugahara et al., 2010 (Science), Iorns et al. (2016). OSF Registries. Outcome recorded: failed.
We found that coadministration with iRGD peptide did not have an impact on permeability of the chemotherapeutic agent doxorubicin (DOX) in a xenograft model of prostate cancer, whereas the original study reported that it increased the penetrance of this cancer drug (Figure 2B; Sugahara et al., 2010). Further, in mice bearing orthotopic 22Rv1 human prostate tumors, we did not find a statistically significant difference in tumor weight for mice treated with DOX and iRGD…
Outcome read from the abstract. View paper
Cite this record
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010). Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs. Science, 328(5981), 1031–1035. https://doi.org/10.1126/science.1183057
Other studies in the atlas
Failed replications · Successful replications · All browse pages